A White House deal with Eli Lilly & Co. and Novo Nordisk to lower the prices of their popular obesity medicines, Zepbound and Wegovy, is a step toward making them more affordable and accessible to Americans — but until we have more details, it’s hard to tell how big a step it really is.

The agreement, announced Thursday by the Trump administration, has several key components. For the first time, Medicare will cover obesity medicines, allowing older Americans who qualify for the drugs to obtain them for a $50 monthly copay. Medicaid and Medicare will pay $245 per month for Lilly and Novo Nordisk’s GLP-1 drugs used to treat both diabetes and obesity. Meanwhile, Americans outside of these programs will be able to purchase them at a discount through the new platform, TrumpRx.

Lilly and Novo

See Full Page